Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA.
Sunami K, Bando H, Yatabe Y, Naito Y, Takahashi H, Tsuchihara K, Toyooka S, Mimori K, Kohsaka S, Uetake H, Kinoshita I, Komine K, Takeda M, Hayashida T, Tamura K, Nishio K, Yamamoto N; Working Group of a Joint Task Force of Three Academic Societies for the Promotion of Cancer Genomic Medicine. Sunami K, et al. Among authors: toyooka s. Cancer Sci. 2021 Sep;112(9):3911-3917. doi: 10.1111/cas.15022. Epub 2021 Jul 12. Cancer Sci. 2021. PMID: 34128569 Free PMC article.
The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.
Toyooka S, Matsuo K, Shigematsu H, Kosaka T, Tokumo M, Yatabe Y, Ichihara S, Inukai M, Suehisa H, Soh J, Kiura K, Fong KM, Lee H, Wistuba II, Gazdar AF, Mitsudomi T, Date H. Toyooka S, et al. Clin Cancer Res. 2007 Oct 1;13(19):5763-8. doi: 10.1158/1078-0432.CCR-07-0216. Clin Cancer Res. 2007. PMID: 17908966 Free article.
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
Toyooka S, Takano T, Kosaka T, Hotta K, Matsuo K, Ichihara S, Fujiwara Y, Soh J, Otani H, Kiura K, Aoe K, Yatabe Y, Ohe Y, Mitsudomi T, Date H. Toyooka S, et al. Cancer Sci. 2008 Feb;99(2):303-8. doi: 10.1111/j.1349-7006.2007.00688.x. Cancer Sci. 2008. PMID: 18271929 Free PMC article.
Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.
Jida M, Toyooka S, Mitsudomi T, Takano T, Matsuo K, Hotta K, Tsukuda K, Kubo T, Yamamoto H, Yamane M, Oto T, Sano Y, Kiura K, Yatabe Y, Ohe Y, Date H, Miyoshi S. Jida M, et al. Among authors: toyooka s. Cancer Sci. 2009 Oct;100(10):1931-4. doi: 10.1111/j.1349-7006.2009.01273.x. Epub 2009 Jul 2. Cancer Sci. 2009. PMID: 19650855 Free PMC article.
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
Minami D, Takigawa N, Kato Y, Kudo K, Isozaki H, Hashida S, Harada D, Ochi N, Fujii M, Kubo T, Ohashi K, Sato A, Tanaka T, Hotta K, Tabata M, Toyooka S, Tanimoto M, Kiura K. Minami D, et al. Among authors: toyooka s. Cancer Sci. 2015 Oct;106(10):1296-302. doi: 10.1111/cas.12752. Epub 2015 Sep 19. Cancer Sci. 2015. PMID: 26211743 Free PMC article.
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Asano H, Soh J, Tsukuda K, Nagasaka T, Fujiwara T, Toyooka S. Yoshioka T, et al. Among authors: toyooka s. Cancer Sci. 2018 Apr;109(4):1166-1176. doi: 10.1111/cas.13546. Epub 2018 Mar 25. Cancer Sci. 2018. PMID: 29465762 Free PMC article.
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S. Torigoe H, et al. Among authors: toyooka s. Cancer Sci. 2018 May;109(5):1493-1502. doi: 10.1111/cas.13571. Epub 2018 Apr 15. Cancer Sci. 2018. PMID: 29532558 Free PMC article.
572 results